Find link

language:

Find link is a tool written by Edward Betts.

searching for Tyrosine kinase inhibitor 89 found (189 total)

alternate case: tyrosine kinase inhibitor

Bcr-Abl tyrosine-kinase inhibitor (6,383 words) [view diff] exact match in snippet view article find links to article

regarded as first generation drug since it is the first Bcr-Abl tyrosine kinase inhibitor to be used in the treatment of CML. In the development of imatinib

Bruton's tyrosine kinase (2,366 words) [view diff] exact match in snippet view article find links to article

that inhibit BTK: Ibrutinib (Imbruvica), a selective Bruton's tyrosine kinase inhibitor. Acalabrutinib (Calquence), approved in October 2017 for relapsed

Poseltinib (123 words) [view diff] exact match in snippet view article find links to article

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi

FAS-AS1 (357 words) [view diff] exact match in snippet view article find links to article

correspondingly decrease expression of sFas. Treatment with Bruton's tyrosine kinase inhibitor or EZH2 knockdown decreases the levels of EZH2, RBM5 and sFas

Saracatinib (592 words) [view diff] no match in snippet view article find links to article

inhibitor, with selective actions as a Src inhibitor and a Bcr-Abl tyrosine-kinase inhibitor. It was originally under development for the treatment of cancer

Roy S. Herbst (1,334 words) [view diff] exact match in snippet view article find links to article

Physicians. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell

BeiGene (2,448 words) [view diff] exact match in snippet view article find links to article

tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. In addition to clinical research, BeiGene's early business model

Bafetinib (733 words) [view diff] no match in snippet view article find links to article

phase II clinical trials in 2010. Imatinib was the first Bcr-Abl tyrosine-kinase inhibitor and was highly successful in treatment of chronic myelogenous

Bronchorrhea (784 words) [view diff] exact match in snippet view article find links to article

cause; they include: gefitinib - epidermal growth factor receptor tyrosine kinase inhibitor indomethacin corticosteroids octreotide radiation therapy bronchoscopy

AEE788 (288 words) [view diff] exact match in snippet view article find links to article

receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity". Cancer Res. 64 (14):

Anti-VEGF (1,671 words) [view diff] exact match in snippet view article find links to article

and metastasis of tumours. AZ2171 (cediranib), a multi-targeted tyrosine kinase inhibitor has been shown to have anti-edema effects by reducing the permeability

ARIAD Pharmaceuticals (1,353 words) [view diff] exact match in snippet view article find links to article

Emeritus as of January 2016. ARIAD developed Ponatinib (Iclusig), a tyrosine kinase inhibitor for the treatment of adult patients with Philadelphia chromosome-positive

Jiban Jyoti Panda (970 words) [view diff] case mismatch in snippet view article find links to article

Nanotubes for Sustained Intravitreal Delivery of a Multi-targeted Tyrosine Kinase Inhibitor. J Control Release. 2016 Sep 10;237:186. doi: 10.1016/j.jconrel

KCNK16 (393 words) [view diff] exact match in snippet view article find links to article

"Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein". Br. J. Pharmacol. 154 (8): 1680–90. doi:10.1038/bjp

GlaxoSmithKline Prize (135 words) [view diff] exact match in snippet view article find links to article

Nicholas Lydon "for the development of the drug imatinib, a targeted tyrosine kinase inhibitor that has transformed the treatment of chronic myelogenous leukaemia

Plexxikon (355 words) [view diff] exact match in snippet view article find links to article

ClinicalTrials.gov". Clinical Trials. Retrieved 2020-10-09. "Fms/Trk tyrosine kinase inhibitor PLX7486". NCI Drug Dictionary. National Cancer Institute. "Phase

Targeted covalent inhibitors (2,061 words) [view diff] exact match in snippet view article find links to article

epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor". Proceedings of the National Academy of Sciences of the United

Midostaurin (567 words) [view diff] exact match in snippet view article find links to article

mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412". Cancer Cell. 1 (5): 433–43. doi:10.1016/S1535-6108(02)00069-7

Infantile myofibromatosis (3,742 words) [view diff] exact match in snippet view article find links to article

mutant proteins in IMF are constitutively overactive and that the tyrosine kinase inhibitor imatinib blocks the activity of the p.Arg561Cys and p.Asn666Lys

KCNK13 (497 words) [view diff] exact match in snippet view article find links to article

"Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein". Br. J. Pharmacol. 154 (8): 1680–90. doi:10.1038/bjp

KCNK10 (539 words) [view diff] exact match in snippet view article find links to article

"Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein". British Journal of Pharmacology. 154 (8): 1680–90

Lymphangiectasia (1,002 words) [view diff] case mismatch in snippet view article find links to article

PMID 17236361. Awiwi, Muhammad O.; Naik, Sagar (7 June 2022). "Tyrosine Kinase Inhibitor–related Intestinal Lymphangiectasia". Radiology. 305 (2): 220137

Piceatannol (758 words) [view diff] exact match in snippet view article find links to article

5'-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor". Biochem. Biophys. Res. Commun. 165 (1): 241–5. doi:10

PP2 (kinase inhibitor) (319 words) [view diff] exact match in snippet view article

(1996). "Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation". The Journal

Nicholas Lydon (660 words) [view diff] exact match in snippet view article find links to article

Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. (2000). "Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit

Spectrum Pharmaceuticals (1,093 words) [view diff] exact match in snippet view article find links to article

based on 643 early-stage breast cancer patients. Poziotinib is a tyrosine kinase inhibitor in development for use in patients with previously treated locally

Gastrointestinal stromal tumor (4,411 words) [view diff] exact match in snippet view article find links to article

resistance to targeted therapy drugs like imatinib mesylate, a tyrosine kinase inhibitor. KIT-p.D419del (exon 8) — A subset of gastrointestinal stromal

CDH11 (1,192 words) [view diff] exact match in snippet view article find links to article

xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor". Oncogene. 23 (8): 1618–26. doi:10.1038/sj.onc.1207268. PMID 14985702

Alexander Levitzki (902 words) [view diff] case mismatch in snippet view article find links to article

Levitzki, Alexander; Rizzoli, Vittorio (1999). "Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous

FGFR1OP (612 words) [view diff] exact match in snippet view article find links to article

Molecular function protein homodimerization activity protein tyrosine kinase inhibitor activity protein binding protein tyrosine kinase activity protein

CYP2C8 (1,464 words) [view diff] exact match in snippet view article find links to article

repaglinide (antidiabetic) torasemide (loop diuretic) sorafenib (tyrosine kinase inhibitor) rosiglitazone (antidiabetic) - converted to active metabolites

Quinazoline (1,240 words) [view diff] exact match in snippet view article find links to article

Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors". Ann Pharmacother. 40 (2): 261–9

WWTR1 (2,330 words) [view diff] exact match in snippet view article find links to article

Cucurbitacin I JAK/STAT3 inhibitor Dasatinib Tyrosine kinase inhibitor Fluvastatin Statin Pazopanib Tyrosine kinase inhibitor Verteporfin TEAD inhibitor Inhibits

Epidermal growth factor receptor (6,879 words) [view diff] exact match in snippet view article find links to article

recently AstraZeneca has developed Osimertinib, a third generation tyrosine kinase inhibitor. Many therapeutic approaches are aimed at the EGFR. Cetuximab

Bempegaldesleukin (599 words) [view diff] case mismatch in snippet view article find links to article

Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for

Joachim Drevs (481 words) [view diff] case mismatch in snippet view article find links to article

222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional

Staurosporine (1,168 words) [view diff] exact match in snippet view article find links to article

et al. (2013). "High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile"

John Kuriyan (624 words) [view diff] exact match in snippet view article find links to article

BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid

John Kuriyan (624 words) [view diff] exact match in snippet view article find links to article

BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid

Proto-oncogene tyrosine-protein kinase Src (2,794 words) [view diff] exact match in snippet view article find links to article

proliferation, migration and invasive potential. So the use of a tyrosine kinase inhibitor is a possible way of reducing the progression of prostate cancers

STAT5 (1,215 words) [view diff] exact match in snippet view article find links to article

S, Ruggeri B, Dionne C, Small D (June 2002). "A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo". Blood. 99

PDGFRB (3,403 words) [view diff] exact match in snippet view article find links to article

patients with similarly appearing neoplasms, respond well to the tyrosine kinase inhibitor, imatinib. The drug often causes long-term complete hematological

Surufatinib (229 words) [view diff] exact match in snippet view article find links to article

Han X, Wu Y, et al. (2023). "Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation

Brain-derived neurotrophic factor (5,339 words) [view diff] exact match in snippet view article find links to article

the presence of a specific NR2B antagonist or a trk receptor tyrosine kinase inhibitor. Thus, it appears BDNF can upregulate the expression and synaptic

Mesoblastic nephroma (2,202 words) [view diff] exact match in snippet view article find links to article

disease might benefit by adding the ALK inhibitor, crizotinib, or a tyrosine kinase inhibitor, either larotrectinib or entrectinib, to surgical, radiation,

Mark Cushman (2,813 words) [view diff] exact match in snippet view article find links to article

cytotoxic natural product that targets myosin; lavendustin A (VI), a tyrosine kinase inhibitor; and (+)- and (–)-corynoline. Professor Cushman has received various

Immunohistochemistry (3,341 words) [view diff] exact match in snippet view article find links to article

detected by immunohistochemistry. Imatinib, an intracellular tyrosine kinase inhibitor, was developed to treat chronic myelogenous leukemia, a disease

Mastocytoma (2,280 words) [view diff] case mismatch in snippet view article find links to article

Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant)

Ipsen (2,137 words) [view diff] exact match in snippet view article find links to article

capital) as of 31 December 2021: Cabometyx (cabozantinib) is a tyrosine kinase inhibitor (TKI) used in the treatment of advanced kidney cancer (renal cell

Receptor for activated C kinase 1 (2,598 words) [view diff] exact match in snippet view article find links to article

binding SH2 domain binding signaling adaptor activity protein tyrosine kinase inhibitor activity protein binding enzyme binding cysteine-type endopeptidase

CD135 (1,728 words) [view diff] exact match in snippet view article find links to article

associated with adverse disease outcome. Gilteritinib, a dual FLT3-AXL tyrosine kinase inhibitor has completed a phase 3 trial of relapsed/refractory acute myeloid

TEC (gene) (2,433 words) [view diff] exact match in snippet view article

kinase inhibitors are largely used for treatment. Dasatinib is a tyrosine kinase inhibitor that has been found to bind to Tec kinase and Btk, limiting release

Pulmonary fibrosis (3,171 words) [view diff] exact match in snippet view article find links to article

Richeldi L, Costabel U, Selman M, et al. (2011). "Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis". N Engl J Med. 365 (12): 1079–1087

Dermatofibrosarcoma protuberans (3,131 words) [view diff] exact match in snippet view article find links to article

dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment". Genes Chromosomes Cancer. 37 (1): 1–19. doi:10.1002/gcc

HYAL2 (1,152 words) [view diff] exact match in snippet view article find links to article

hyaluronic acid binding enzyme binding receptor signaling protein tyrosine kinase inhibitor activity hydrolase activity transforming growth factor beta binding

Inflammatory breast cancer (2,651 words) [view diff] exact match in snippet view article find links to article

P, et al. (November 2009). "Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis

AXL receptor tyrosine kinase (2,326 words) [view diff] exact match in snippet view article find links to article

is currently testing gilteritinib (ASP2215), a dual FLT3-AXL tyrosine kinase inhibitor in acute myeloid leukemia (AML). In 2017, gilteritinib gained

Hepatocyte growth factor receptor (6,895 words) [view diff] exact match in snippet view article find links to article

"Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor". Toxicologic Pathology. 38 (3): 416–28. doi:10.1177/0192623310364027

Fibroblast growth factor receptor 2 (1,748 words) [view diff] exact match in snippet view article find links to article

have been found in endometrial cancer and melanoma. AZD4547 is a tyrosine kinase inhibitor which targets FGFR1-3. It has demonstrated early evidence of efficacy

Follicular lymphoma (7,965 words) [view diff] exact match in snippet view article find links to article

cells, and then infused back into the donor patient); 3) Bruon's tyrosine kinase inhibitor, ibrutinib, to block the B-cell maturating actions of this kianase;

Acute myeloblastic leukemia with maturation (3,160 words) [view diff] exact match in snippet view article find links to article

because it also forms a fusion oncoprotein – BCR-Abl. The developed tyrosine kinase inhibitor, imatinib mesylate, has had a tremendous effect on stopping cancer

Timeline of cancer treatment development (2,580 words) [view diff] no match in snippet view article find links to article

gene therapy treatment of cancer (melanoma) 1992 – Invention of tyrosine-kinase inhibitor Imatinib 1992 – Invention of Etacstil breast cancer anti-estrogen

Scleroderma (3,463 words) [view diff] exact match in snippet view article find links to article

sinusoidal obstruction syndrome, malignancy and SIADH Dasatinib Tyrosine kinase inhibitor against various proangiogenic growth factors (including PDGF and

ERBB3 (2,750 words) [view diff] exact match in snippet view article find links to article

Hann B, Shokat KM, Moasser MM (2007). "Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3". Nature. 445 (7126): 437–41

Brexucabtagene autoleucel (1,250 words) [view diff] exact match in snippet view article find links to article

bendamustine-containing chemotherapy, an anti-CD20 antibody, and a Bruton tyrosine kinase inhibitor. Participants received a single infusion of brexucabtagene autoleucel

Ulocladium botrytis (2,136 words) [view diff] case mismatch in snippet view article find links to article

König, Gabriele M.; Wright, Anthony D. (November 1999). "A New Tyrosine Kinase Inhibitor from a Marine Isolate of Ulocladium botrytis and New Metabolites

Drug design (4,974 words) [view diff] exact match in snippet view article find links to article

1995. Another case study in rational drug design is imatinib, a tyrosine kinase inhibitor designed specifically for the bcr-abl fusion protein that is characteristic

ABL (gene) (3,496 words) [view diff] no match in snippet view article

ABL1 kinase domain (blue) in complex with the second-generation Bcr-Abl tyrosine-kinase inhibitor nilotinib (red)

Induced pluripotent stem cell (10,587 words) [view diff] exact match in snippet view article find links to article

Matsa, Elena (15 February 2017). "High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells". Science

Short linear motif (4,034 words) [view diff] exact match in snippet view article find links to article

Gleevec® specially targets bcr-abl and Sprycel® is a broad-based tyrosine kinase inhibitor whose targets include Bcr-Abl and Src. Cleavage is another process

Thyroid cancer (5,381 words) [view diff] exact match in snippet view article find links to article

these agents to negotiate the approval process is vandetanib, a tyrosine kinase inhibitor that targets the RET proto-oncogene, two subtypes of the vascular

Anaplastic lymphoma kinase (5,299 words) [view diff] exact match in snippet view article find links to article

intolerant to crizotinib. Entrectinib (RXDX-101) is a selective tyrosine kinase inhibitor developed by Ignyta, Inc., with specificity, at low nanomolar

List of OMIM disorder codes (18,877 words) [view diff] exact match in snippet view article find links to article

deficiency of; 201470; ACADS Adenocarcinoma of lung, response to tyrosine kinase inhibitor in; 211980; EGFR Adenocarcinoma of lung, somatic; 211980; BRAF

Guo Mei (1,559 words) [view diff] case mismatch in snippet view article find links to article

J Clin Oncol 2015 "Efficacy of Switching to 2nd Generation of Tyrosine Kinase Inhibitor on CML Patients at Poor Responses to Imatinib" 2014 "Comparison

Ribavirin (4,708 words) [view diff] case mismatch in snippet view article find links to article

mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis

FIP1L1 (3,198 words) [view diff] exact match in snippet view article find links to article

great success and long term remissions using low dosages of the tyrosine kinase inhibitor, Imatinib. This drug, also known as Gleevec, has been a FDA-approved

Platelet-derived growth factor receptor A (3,354 words) [view diff] exact match in snippet view article find links to article

some PDGFRA mutation-induced GIST tumors are sensitive to the tyrosine kinase inhibitor, imatinib, the most common mutation, D842V, as well as some very

Inflammatory myofibroblastic tumour (3,914 words) [view diff] exact match in snippet view article find links to article

development of an abnormal EKG (i.e. QT prolongation). Entrectinib, a tyrosine kinase inhibitor that is active on ROS1 and NRTK as well as AKT, has shown clinically

Anaplastic large-cell lymphoma (5,218 words) [view diff] case mismatch in snippet view article find links to article

ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series". Journal of Pediatric Hematology/Oncology

Lipid raft (6,643 words) [view diff] exact match in snippet view article find links to article

localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib". Journal of Cellular Physiology. 226 (9): 2316–2328

LIG3 (3,805 words) [view diff] exact match in snippet view article find links to article

2013). "Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias". Oncogene. 32 (14): 1784–93

AstraZeneca (7,811 words) [view diff] exact match in snippet view article find links to article

gain commercial rights to Acerta's irreversible oral Bruton's tyrosine kinase inhibitor, acalabrutinib (ACP-196), which is currently in Phase III development

C-Met inhibitor (3,549 words) [view diff] case mismatch in snippet view article find links to article

Bono, Johann S.; Eskens, Ferry A. L. M. (2015-05-15). "The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble

EIF4E (8,380 words) [view diff] case mismatch in snippet view article find links to article

mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis

Regulatory T cell (9,560 words) [view diff] no match in snippet view article find links to article

signaling is also possible by blocking tyrosine kinases. For example, tyrosine-kinase inhibitor dasatinib is used for treatment of chronic myeloid leukemia and

Research in multiple sclerosis (7,886 words) [view diff] exact match in snippet view article find links to article

brain atrophy reduction in secondary progressive MS. Masitinib, a tyrosine kinase inhibitor, is in late-stage testing for the treatment of patients with secondary

Eli Lilly and Company (15,118 words) [view diff] exact match in snippet view article find links to article

Pharmaceutical in developing and commercialising Hanmi's phase I Bruton's tyrosine kinase inhibitor HM71224 in a deal which could yield $690 million. A day later

Treatment of lung cancer (6,487 words) [view diff] exact match in snippet view article find links to article

most benefit from gefitinib. Erlotinib (Tarceva), another EGFR tyrosine kinase inhibitor, increased survival in non-small cell lung cancer and was approved

Engineered CAR T cell delivery (3,553 words) [view diff] exact match in snippet view article find links to article

Michel; Einsele, Hermann; Hudecek, Michael (Jul 2019). "The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells"